Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,670,992
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.63
  • Price/Sales 8.32
  • Price/Cash Flow 22.35
  • Price/Book 17.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.41 +7.51%
on 11/14/17
53.12 unch
on 12/12/17
+3.21 (+6.43%)
since 11/10/17
3-Month
47.35 +12.19%
on 10/13/17
53.12 unch
on 12/12/17
+4.60 (+9.48%)
since 09/12/17
52-Week
32.83 +61.80%
on 02/02/17
53.12 unch
on 12/12/17
+17.47 (+49.00%)
since 12/12/16

Most Recent Stories

More News
Diabetes Drugs Market Value to Reach US$58.4 billion by the End of 2025: Transparency Market Research

Transparency Market Research observes that the global diabetes drugs market is likely to witness intense competition in the coming years due to a strong presence of several vendors. Companies operating...

BAYRY : 31.2450 (+0.44%)
NVO : 53.07 (+1.24%)
MRK : 56.85 (+0.91%)
Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target

Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.

PBR : 9.67 (-0.72%)
SNP : 70.83 (-0.38%)
BMO : 78.15 (-0.27%)
NVO : 53.07 (+1.24%)
RIO : 47.96 (+0.02%)
SNE : 44.62 (-0.62%)
RHHBY : 30.3050 (+0.15%)
VALE : 10.82 (-0.18%)
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

MYL : 39.95 (+1.16%)
NVO : 53.07 (+1.24%)
JNJ : 143.02 (+1.33%)
LLY : 86.19 (-0.55%)
RHHBY : 30.3050 (+0.15%)
GSK : 35.52 (+0.59%)
SNY : 43.86 (+0.37%)
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

AZN : 33.35 (+0.69%)
NVO : 53.07 (+1.24%)
MRK : 56.85 (+0.91%)
SNY : 43.86 (+0.37%)
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide...

NVO : 53.07 (+1.24%)
Global Insulin Delivery Pen Market Analysis 2012-2017 - Forecasts 2018-2025 Featuring Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford, Ypsomed & Biocon

The "Global Insulin Delivery Pen Market Analysis, Size, Share, Segmentation and Competitive Landscape (2012 - 2017) and Future Forecast (2018 - 2025)" report has been added to Research and Markets' offering....

NVO : 53.07 (+1.24%)
LLY : 86.19 (-0.55%)
Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

CVS : 72.61 (-0.64%)
NVO : 53.07 (+1.24%)
JNJ : 143.02 (+1.33%)
SNY : 43.86 (+0.37%)
Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

MYL : 39.95 (+1.16%)
NVO : 53.07 (+1.24%)
JNJ : 143.02 (+1.33%)
TEVA : 16.68 (+1.46%)
PFE : 36.65 (+1.22%)
GSK : 35.52 (+0.59%)
BMY : 63.47 (+0.71%)
Dow Soars Past 24K; Finishes 8th Month in the Green

Dow Soars Past 24K; Finishes 8th Month in the Green

BR : 89.52 (-0.31%)
NVO : 53.07 (+1.24%)
RTH : 90.91 (+0.03%)
DB : 19.25 (-0.26%)
GSK : 35.52 (+0.59%)
LGF.A : 31.15 (-0.57%)
5 Biotech and Pharma Stocks with FDA Catalysts this December

As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.

MYL : 39.95 (+1.16%)
NVO : 53.07 (+1.24%)
NVS : 84.05 (+0.30%)
GILD : 74.96 (-1.21%)
AMGN : 174.40 (-1.37%)
VRX : 21.69 (+5.55%)
ACRS : 24.90 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 52.86
1st Resistance Point 52.64
Last Price 53.07
1st Support Level 52.16
2nd Support Level 51.90

See More

52-Week High 53.12
Last Price 53.07
Fibonacci 61.8% 45.37
Fibonacci 50% 42.97
Fibonacci 38.2% 40.58
52-Week Low 32.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.